Skip to main content
Log in

Antibiotic Stewardship – eine Einführung

Antibiotic stewardship—An introduction

  • Leitthema
  • Published:
Zeitschrift für Pneumologie Aims and scope

Zusammenfassung

Antibiotic Stewardship (ABS) hat den rationalen Einsatz von Antibiotika in allen Bereichen der Humanmedizin zum Ziel. Zunehmend geht es jedoch nicht nur um Antibiotika, sondern um Antiinfektiva allgemein. Hauptgrund für die Implementierung von ABS ist die besorgniserregende, bakterielle Resistenzentwicklung weltweit, die auf einen steigenden Einsatz von Antibiotika zurückzuführen ist, mit einer Zunahme des globalen Antibiotikaverbrauchs um 65 % vom Jahr 2000 bis zum Jahr 2015. In Deutschland hinkt die ABS-Bewegung zwar grundsätzlich anderen Ländern hinterher, hat jedoch in den letzten Jahren große Fortschritte gemacht. Allen voran werden interdisziplinäre ABS-Teams in Krankenhäusern eingerichtet. Jedoch werden zunehmend auch ABS-Projekte auf der Ebene einer Stadt oder einer Region etabliert, die v. a. auch niedergelassene Ärzte einschließen, und nationale Bemühungen wie die Klug entscheiden-Empfehlungen der Deutschen Gesellschaft für Innere Medizin (DGIM) stellen Ergänzungen dar. All diese Anstrengungen lohnen sich, wie viele Publikationen zeigen, dass nämlich der Antibiotikaverbrauch durch ABS-Maßnahmen deutlich gesenkt werden kann. Aufwendige, über viele Jahre durchgeführte Auswertungen können auch zeigen, dass durch ABS-Interventionen tatsächlich die bakterielle Resistenzrate gesenkt wird. Dies trifft auf Deutschland ebenfalls zu. Eine Analyse, die 2020 publiziert wurde, zeigt, dass der Antibiotikaverbrauch in Deutschland langsam gesenkt wird, insbesondere in der Kinder- und Jugendmedizin. Substanzen wie Cephalosporine und Fluorchinolone werden weniger eingesetzt, wohingegen Aminopenicilline häufiger verwendet werden – ganz im Sinne von ABS.

Abstract

The goal of antibiotic stewardship (ABS) is a rational administration of antibiotics in all areas of human medicine; however, the idea increasingly applies not only to antibiotics but to anti-infective agents in general. The main reason for the implementation of ABS is the alarming global development of bacterial resistance, which can be attributed to the increasing use of antibiotics globally with a 65% rise in antibiotic consumption from 2000 to 2015. For some time Germany dragged behind many other countries in terms of ABS; however, within the past few years substantial progress has been made. Specifically, interdisciplinary ABS teams are being established in German hospitals; however, ABS projects at the level of a town or a geographic region are also being established, which particularly include general practitioners, and national efforts, such as the choosing wisely recommendations of the German Society of Internal Medicine (DGIM), supplement these efforts. All these efforts are worthwhile as many publications show. By implementing ABS measures the use of antibiotics can be clearly reduced. Very elaborate evaluations conducted over many years were also able to show that the bacterial resistance rate is actually reduced by ABS interventions. This holds true for Germany as well. An analysis that was published in 2020 showed that the antibiotic consumption is decreasing slowly in Germany, especially in the pediatric and adolescent medicine sector. Substances, such as cephalosporins and fluoroquinolones are used in decreasing amounts, whereas aminopenicillins are applied more often, in line with ABS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Antimicrobial Resistance C (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399(10325):629–655. https://doi.org/10.1016/S0140-6736(21)02724-0

    Article  Google Scholar 

  2. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS et al (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 19(1):56–66. https://doi.org/10.1016/S1473-3099(18)30605-4

    Article  PubMed  PubMed Central  Google Scholar 

  3. Noll IE, Eckmanns T, Sin M‑A (2020) Antibiotikaresistenzen: ein heterogenes Bild. Dtsch Arztebl 117(1–2):A-28

    Google Scholar 

  4. Wilke MH, Preisendorfer B, Seiffert A, Kleppisch M, Schweizer C, Rauchensteiner S (2022) Carbapenem-resistant gram-negative bacteria in Germany: incidence and distribution among specific infections and mortality: an epidemiological analysis using real-world data. Infection. https://doi.org/10.1007/s15010-022-01843-6

    Article  PubMed  Google Scholar 

  5. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA et al (2018) Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A 115(15):E3463–E3470. https://doi.org/10.1073/pnas.1717295115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bruyndonckx R, Adriaenssens N, Versporten A, Hens N, Monnet DL, Molenberghs G et al (2021) Consumption of antibiotics in the community, European Union/European Economic Area, 1997–2017. J Antimicrob Chemother 76(12 Suppl 2):ii7–ii13. https://doi.org/10.1093/jac/dkab172

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lehmann C, Berner R, Bogner JR, Cornely OA, de With K, Herold S et al (2017) The “Choosing Wisely” initiative in infectious diseases. Infection 45(3):263–268. https://doi.org/10.1007/s15010-017-0997-0

    Article  PubMed  Google Scholar 

  8. Draenert R, Jung N (2020) Choosing Wisely in Infectious Diseases—important recommendations for daily life in medicine. MMW Fortschr Med 162(6):53–56. https://doi.org/10.1007/s15006-020-0342-x

    Article  PubMed  Google Scholar 

  9. Draenert R, Jung N, Choosing Wisely DGIWG (2020) Update on the “Choosing Wisely” initiative in infectious diseases in Germany. Infection 48(3):317–321. https://doi.org/10.1007/s15010-020-01400-z

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gruber MM, Weber A, Jung J, Werner J, Draenert R (2021) Impact and sustainability of antibiotic stewardship on antibiotic prescribing in visceral surgery. Antibiotics. https://doi.org/10.3390/antibiotics10121518

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pouwels KB, Hopkins S, Llewelyn MJ, Walker AS, McNulty CA, Robotham JV (2019) Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. BMJ 364:l440. https://doi.org/10.1136/bmj.l440

    Article  PubMed  PubMed Central  Google Scholar 

  12. Peragine C, Walker SAN, Simor A, Walker SE, Kiss A, Leis JA (2020) Impact of a comprehensive antimicrobial stewardship program on institutional burden of antimicrobial resistance: a 14–year controlled interrupted time-series study. Clin Infect Dis 71(11):2897–2904. https://doi.org/10.1093/cid/ciz1183

    Article  CAS  PubMed  Google Scholar 

  13. Hecker MT, Fox CJ, Son AH, Cydulka RK, Siff JE, Emerman CL et al (2014) Effect of a stewardship intervention on adherence to uncomplicated cystitis and pyelonephritis guidelines in an emergency department setting. Plos One 9(2):e87899. https://doi.org/10.1371/journal.pone.0087899

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Borde JP, Kern WV, Hug M, Steib-Bauert M, de With K, Busch HJ et al (2015) Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department. Emerg Med J 32(7):509–515. https://doi.org/10.1136/emermed-2014-204067

    Article  PubMed  Google Scholar 

  15. Alvarez-Marin R, Lopez-Cerero L, Guerrero-Sanchez F, Palop-Borras B, Rojo-Martin MD, Ruiz-Sancho A et al (2021) Do specific antimicrobial stewardship interventions have an impact on carbapenem resistance in Gram-negative bacilli? A multicentre quasi-experimental ecological study: time-trend analysis and characterization of carbapenemases. J Antimicrob Chemother 76(7):1928–1936. https://doi.org/10.1093/jac/dkab073

    Article  CAS  PubMed  Google Scholar 

  16. Holstiege J, Schulz M, Akmatov MK, Kern WV, Steffen A, Batzing J (2020) The Decline in Outpatient Antibiotic Use. Dtsch Arztebl Int 117(41):679–686. https://doi.org/10.3238/arztebl.2020.0679

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rika Draenert.

Ethics declarations

Interessenkonflikt

R. Draenert gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

J. Rademacher, Hannover

T. Welte, Hannover

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Draenert, R. Antibiotic Stewardship – eine Einführung. Z Pneumologie 19, 335–342 (2022). https://doi.org/10.1007/s10405-022-00472-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-022-00472-y

Schlüsselwörter

Keywords

Navigation